argenx to provide updates on ARGX-113 and ARGX-110 during American Society of Hematology Annual Meeting
December 02, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Workshop to occur on Sunday December 4th...
argenx to Present at Upcoming Investor Conferences
November 08, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent,...
argenx Reports Third Quarter 2016 Financial Results and Provides Business Update
October 27, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent,...
Frost & Sullivan Applauds argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPLE Antibody(TM)
October 05, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
argenx's specific drug candidates...
argenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York
September 22, 2016 12:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Myasthenia gravis and immune...
argenx to host inaugural R&D day and webcast on September 22, 2016
September 15, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent,...
argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results
August 26, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Successful Phase 1 multiple...
argenx to Host Conference Call & Webcast to Report Second Quarter 2016 Business Update and Half-Year Financial Results on August 26, 2016
August 19, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent, Belgium - argenx...
argenx to Present at Wedbush PacGrow Healthcare Conference
August 10, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent, Belgium...
argenx announces initial results from Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers
June 30, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Data show potent reduction of IgG...